Pharmaceuticals News and Research

RSS

USPTO allows Isis an additional patent for single-stranded RNAi technology

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.

11 Sep 2009

Bioidentical hormone therapy is safe and effective for menopausal women

Life Extension(R), the company that long ago sounded the alarm on the dangers of synthetic hormone replacement therapy for menopausal women, has published still more proof that bioidentical hormones offer a far safer treatment option.

11 Sep 2009

PCMA stresses on improving affordability in the health care system

“Pharmacy benefit managers (PBMs) share the President’s goal of improving affordability as a central tenant to reforming the health care system. Tools pioneered by PBMs – including those which increase the use of generic medicines – have accomplished this goal by lowering costs and expanding access to prescription drugs for consumers and payers.

11 Sep 2009

BioOhio and GCIC launch Ohio Bioscience Resource Directory

BioOhio and the Global Cardiovascular Innovation Center (GCIC) have launched an expanded and improved Ohio Bioscience Resource Directory, the most comprehensive online collection of Ohio companies, organizations, and research centers involved in the biosciences.

11 Sep 2009

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

MAP Pharmaceuticals, Inc. announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX orally inhaled migraine therapy, currently in development, at the 14th Congress of the International Headache Society.

11 Sep 2009

HHS Secretary to issue new report on the employer-sponsored insurance market

HHS Secretary Kathleen Sebelius today will address the University of Chicago’s dialogue on health care reform and education and issue a new report on the employer-sponsored insurance market.

11 Sep 2009

ThromboGenics shortlisted for two awards at the Scrip Awards 2009

ThromboGenics NV, a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009.

11 Sep 2009

Tetraphase to present its study on novel classes of antibiotics to treat drug-resistant infections

Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough synthetic chemistry technology announced today that it will present three (3) posters and deliver a slide presentation on the synthesis and antibacterial activity of analogs from several novel classes of antibiotics to treat drug-resistant infections at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA.

11 Sep 2009

Update on Prolindac clinical development plan provided by Access Pharmaceuticals

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on the Company's clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies.

11 Sep 2009

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will center on Amylin's "phybrid" technology.

11 Sep 2009

Recession hits some biopharmaceutical companies and CROs

Recession-driven slowdowns in drug development mean problems for some biopharmaceutical companies and, by extension, the contract research organizations (CROs) they employ to test prospective therapies.

11 Sep 2009

Positive results from Mpex' Phase 2b clinical trial with Aeroquin

Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.

11 Sep 2009

Quintiles partners with the University of Pretoria

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines.

11 Sep 2009

Drug manufacturers are seeking out needle-free systems

Many of the novel biopharmaceutical drugs developed now can only be delivered by injection, and this has biologic manufacturers seeking out the most patient-friendly options, including needle-free systems.

11 Sep 2009

Neurologists recommend oral cladribine for treating multiple sclerosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its infrequent dosing and positive efficacy, nearly 90 percent of surveyed neurologists indicate they will prescribe Merck Serono/EMD Serono's oral cladribine for the treatment of multiple sclerosis.

11 Sep 2009

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

PhRMA concurs with Obama's health care reform

Pharmaceutical Research and Manufacturers of America (PhRMA) President & CEO Billy Tauzin issued the following statement after President Obama's address to a joint session of Congress on health care reform:

11 Sep 2009

Study examines how biotech firm partnerships with developing nations can help increase innovation, revenue

By forging partnerships with developing countries, biotechnology companies from developed countries may be able to stay afloat during the current economic crisis and bolster innovation, according to a study published Thursday in the journal Nature Biotechnology, Livemint.com reports.

11 Sep 2009

Adamis Pharmaceuticals' Epinephrine injection categorized as a generic

Adamis Pharmaceuticals Corporation announced on July 23 that its wholly owned subsidiary, Adamis Labs launched and shipped the first orders of the company’s Epinephrine Injection, USP, 1:1000 (0.3mg prefilled single dose syringe) (“PFS”). Today, Adamis Labs reports that at least two major data base reference companies (Medi-Span® and First DataBank) placed the Company’s PFS in their generic category.

11 Sep 2009

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics announced today that the Company has demonstrated efficacy in preclinical models in two Pepducin projects. One of the projects targets CXCR4, a key regulator of stem cell and inflammatory cell homeostasis. A second project has yielded the first potent Pepducin agonists for an undisclosed cardiovascular target.

11 Sep 2009